Posts in OncoGen Researchers

OncoGen COVID-19 vaccine project recognized by the World Health Organization (WHO)

April 8, 2020 Posted by OncoGen News, OncoGen Researchers 0 thoughts on “OncoGen COVID-19 vaccine project recognized by the World Health Organization (WHO)”

The World Health Organization (WHO) recognized OncoGen, as the only research centre in Romania that has a protein subunit COVID-19 vaccine candidate in pre-clinical tests.

OncoGen joins reputable academic institutions and private companies known for their expertise in the field of vaccine development and high-performing biomedical research.

The full list of candidate vaccines in clinical and pre-clinical tests, as of April 4, 2020, can be found at: https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf

OncoGen researchers propose personalized vaccinomics strategy for the novel China coronavirus

January 29, 2020 Posted by OncoGen Researchers 0 thoughts on “OncoGen researchers propose personalized vaccinomics strategy for the novel China coronavirus”

OncoGen researchers propose a novel approach for producing epitope-based peptide vaccine candidates for the novel China coronavirus (nCoV).

Wuhan seafood market pneumonia virus, also known as 2019 Novel Coronavirus (2019-nCoV) is a relative of both the deadly severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) viruses. According to Nature Briefing, by January 28, the number of confirmed cases has jumped to more than 4,500 with more than 100 people dead as a result of the infection. By comparison, SARS spread globally in 2002-03, infecting 8000 and killing more than 700 people.

Traditional vaccines for viral diseases had limited success in the case of viral epidemics with high mutation rates. The approach that we used for designing potential peptide vaccine candidates takes a more personalized strategy, referred to as vaccinomics, which enables the selection of target viral proteins with low mutation rates, and the design of peptides tuned to the immune characteristics of the target populations, variable based on geographic location and ethnicity.

Based on the human MHC (human leukocyte antigen) allele variation, the peptide vaccines can be made more relevant to a community or individual. The selection of the peptides that could act as vaccines is determined by the binding of the processed viral peptide with the major histocompatibility complex (MHC) class I and II molecules, and the relevant HLA alleles.

Our proposed candidate peptides take into consideration the most frequent HLA alleles found in the Romanian population.

Technical details of the approach used are detailed below:

We identified multiepitope peptide vaccine candidates against nCov that can potentially trigger both CD4+ and CD8+ T cell immune response. To this end, we designed 15-30 aa synthetic long peptides (SLPs), as proposed by Rabu et al. (2019), using a cathepsin-sensitive linker (LLSVGG) for linking MHC class I-restricted epitopes to MHC class II-restricted epitopes, with the MHC class II epitope located always at the N-terminal end, to stimulate both CTLs and T helper lymphocytes (together with innate immune system).

GenBank Acc. No. of coronavirus isolate Wuhan-Hu-1 used for analysis: MN908947.3 which is identical to Ref Seq NC_045512 (provisonal ref seq, under review by NCBI): https://www.ncbi.nlm.nih.gov/nuccore/NC_045512.2

It is an enveloped, positive-sense, single-stranded poly-adenylated RNA virus, with a genome of 29.9 kb (29903 bp), among the largest of all RNA virus genomes.

Complete genomic sequences known to date: S and M proteins important as target for nCoV vaccine; S = spike (for adhesion and fusion); M = membrane (for replication and virion exocytosis).

The tool from the Immune Epitope Database (IEDB) server was used to identify potent T cell epitopes from the sequences of S and M proteins. For CD8+ T cell epitopes, the prediction method integrated MHC class I binding, proteasomal cleavage and TAP transport efficiency. Several epitopes were selected for further analysis based on high overall score and if they showed high MHC binding affinity (IC50 <50 nM) (Table 1). For CD4+ T cell epitopes, the highest ranking peptide based on MHC class II binding was chosen (Table 2).
The class I and class II MHC alleles considered were the most frequent alleles in Romania, according to Constantinescu et al. (2017):

HLA-A*02 (29%)
HLA-A*01 (14.3%)
HLA-A*24 (11.2%)
HLA-B*35 (16%) (superfamily B07)
HLA-B*18 (11%) (superfamily B44)
HLA-DRB1*11 (18.5%)
HLA-DRB1*03 (11.3%)
HLA-DRB1*13 (10.5%)

Synthetic Long Peptide Vaccine candidate for S protein

GNYNYLYRLFRKSNLLSVGGYLQPRTFLL

                                                       YLQPRTFLL    HLA-A*0201 epitope

GNYNYLYRLFRKSN                                            HLA-DRB1*1101 epitope

               LYRLFRKSNLLSVG                               HLA-DRB1*1301 epitope

Synthetic Long Peptide Vaccine candidate for M protein

SYFIASFRLFARTRSLLSVGGGLMWLSYFI

                                                    GLMWLSYFI  HLA-A*0201 epitope

SYFIASFRLFARTRS                                          HLA-DRB1*1101 epitope

        ASFRLFARTRSLLS                                    HLA-DRB1*1301 epitope

Synthetic Long Peptide Vaccine candidate for S and M proteins

SYFIASFRLFARTRSLLSVGGYLQPRTFLL

                                                      YLQPRTFLL  HLA-A*0201 epitope

SYFIASFRLFARTRS                                          HLA-DRB1*1101 epitope

        ASFRLFARTRSLLS                                    HLA-DRB1*1301 epitope

 

The candidate peptides presented above were designed by applying to viral antigens a technology used for personalized vaccination in cancer, based on long neoantigen peptides, currently in clinical trials for cancer therapy.
Based on this model, additional peptide candidates can be identified for populations from different geographic regions of the world.
The current approach is a compromise between an industrial large-scale global vaccination strategy and an individually-targeted personalized vaccination strategy.
We will continue the validation of these candidates and of the model.

Image source: Eye of Science/SPL

Award for OncoGen Researcher at the European Society of Cardiology Meeting in Malaga

October 24, 2019 Posted by OncoGen Researchers 0 thoughts on “Award for OncoGen Researcher at the European Society of Cardiology Meeting in Malaga”

Dr. Greta Bărbulescu presented at the International Conference organized by the European Society of Cardiology (ESC) Working Group – Development, Anatomy and Pathology, in Malaga, Spain, 14-16 October 2019, the research project titled „Innovative biotechnology for generation of cardiac tissue using animal model” which falls under one of the main research areas of the OncoGen centre – regenerative medicine.

The project was coordinated by Prof. Univ. Dr. Virgil Păunescu, Conf. Univ. Dr. Florina Bojin, Dr. Valentin Ordodi and Asist. Univ. Dr. Oana Gavriliuc. The conference was attended by reputable researchers in regenerative medicine, specialists in molecular biology, genetics, morphopathology and cardiology. The presentation received an award at the poster session „Working Group Young Community” and Dr. Bărbulescu was also endowed with a travel award.

Contact

Pius Branzeu Clinical Emergency Hospital
300723 Timisoara, Romania
156, Liviu Rebreanu Boulevard
info@oncogen.ro

© OncoGen Research Centre. 2019. All rights reserved. Website by Ecuson Studio